John Overdeck’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $869K | Sell |
10,654
-16,456
| -61% | -$1.19M | ﹤0.01% | 3713 |
|
|
2026
Q1 | $1.85M | Buy |
27,110
+2,800
| +12% | +$198K | ﹤0.01% | 2812 |
|
|
2025
Q4 | $1.85M | Sell |
24,310
-31
| -0.1% | -$2.25K | ﹤0.01% | 2490 |
|
|
2025
Q3 | $1.49M | Sell |
24,341
-26,510
| -52% | -$1.38M | ﹤0.01% | 2326 |
|
|
2025
Q2 | $2.48M | Sell |
50,851
-29,249
| -37% | -$1.39M | ﹤0.01% | 1683 |
|
|
2025
Q1 | $4.08M | Sell |
80,100
-93,252
| -54% | -$4.65M | 0.01% | 1239 |
|
|
2024
Q4 | $7.83M | Sell |
173,352
-143,945
| -45% | -$6.16M | 0.02% | 863 |
|
|
2024
Q3 | $11.8M | Sell |
317,297
-876
| -0.3% | -$29.3K | 0.03% | 687 |
|
|
2024
Q2 | $9.73M | Buy |
318,173
+121,522
| +62% | +$3.94M | 0.02% | 721 |
|
|
2024
Q1 | $5.72M | Buy |
+196,651
| New | +$5.51M | 0.01% | 904 |
|
|
2023
Q4 | – | Sell |
-132,331
| Closed | -$2.97M | – | 3332 |
|
|
2023
Q3 | $2.97M | Buy |
132,331
+89,059
| +206% | +$3.31M | 0.01% | 1163 |
|
|
2023
Q2 | $1.76M | Sell |
43,272
-90,869
| -68% | -$4.45M | ﹤0.01% | 1526 |
|
|
2023
Q1 | $6.5M | Sell |
134,141
-107,071
| -44% | -$4.89M | 0.02% | 783 |
|
|
2022
Q4 | $9.21M | Sell |
241,212
-65,944
| -21% | -$2.74M | 0.03% | 589 |
|
|
2022
Q3 | $15.4M | Buy |
+307,156
| New | +$15M | 0.05% | 377 |
|
|
2021
Q3 | – | Sell |
-74,489
| Closed | -$3.15M | – | 4609 |
|
|
2021
Q2 | $3.15M | Sell |
74,489
-19,489
| -21% | -$835K | 0.01% | 1512 |
|
|
2021
Q1 | $4.45M | Buy |
93,978
+67,437
| +254% | +$4M | 0.01% | 1133 |
|
|
2020
Q4 | $1.62M | Buy |
+26,541
| New | +$1.56M | ﹤0.01% | 1631 |
|
|
2020
Q2 | – | Sell |
-182,611
| Closed | -$8.15M | – | 3419 |
|
|
2020
Q1 | $8.15M | Sell |
182,611
-92,536
| -34% | -$4.66M | 0.07% | 318 |
|
|
2019
Q4 | $13.2M | Buy |
+275,147
| New | +$11.7M | 0.04% | 511 |
|
|
2018
Q4 | – | Sell |
-45,147
| Closed | -$2.12M | – | 3413 |
|
|
2018
Q3 | $2.12M | Sell |
45,147
-196,394
| -81% | -$8.13M | 0.01% | 1441 |
|
|
2018
Q2 | $8.15M | Sell |
241,541
-416,113
| -63% | -$13M | 0.02% | 754 |
|
|
2018
Q1 | $17.8M | Buy |
657,654
+405,956
| +161% | +$10.3M | 0.06% | 384 |
|
|
2017
Q4 | $4.2M | Buy |
+251,698
| New | +$4.26M | 0.01% | 988 |
|
|
2015
Q3 | – | Sell |
-36,545
| Closed | -$1.76M | – | 2622 |
|
|
2015
Q2 | $1.76M | Sell |
36,545
-141,204
| -79% | -$8.24M | 0.01% | 1278 |
|
|
2015
Q1 | $10.8M | Buy |
+177,749
| New | +$10.8M | 0.05% | 449 |
|
Other funds holding PTCT
RI
JT
John Overdeck's PTCT Position: Q2 2026 in Review
John Overdeck reduced its PTC Therapeutics (PTCT) stake by 61% in Q2 2026, selling an estimated $1.19M and leaving 10,654 shares worth $869K. The position accounts for ﹤0.01% of the portfolio, ranked #3713.
John Overdeck first reported a position in PTCT in Q1 2015 and has held it in 26 quarters since. The position peaked at $17.8M in Q1 2018. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- John Overdeck held 10,654 shares of PTC Therapeutics worth $869K as of Q2 2026.
- John Overdeck sold 16,456 PTC Therapeutics shares in Q2 2026, an estimated $1.19M.
- PTC Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3713 holding.
- John Overdeck first reported a position in PTC Therapeutics in Q1 2015 and has held it in 26 quarters since.
- John Overdeck's PTC Therapeutics position peaked at $17.8M in Q1 2018.
- 380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.